Functional assessment of β adrenoceptor subtypes in human colonic circular and longitudinal (taenia coli) smooth muscle

Gut

Volumn 47, Issue 3, 2000, Pages 337-342

  Manara, L ^a   Croci, T ^a   Aureggi, G ^a   Guagnini, F ^a   Maffrand, J P ^b   Le Fur, G ^b   Mukenge, S ^c   Ferla, G ^c  

^a Research Center Sanofi Midy   (Italy)

^b SANOFI   (France)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

adrenoceptor subtypes; Human colon; Smooth muscle; Taenia coli

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; [[7 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO] 5,6,7,8 TETRAHYDRO 2 NAPHTHYL]OXY]ACETIC ACID ETHYL ESTER; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ISOPRENALINE; PROPRANOLOL; RECEPTOR SUBTYPE; TERBUTALINE;

ADULT; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL ARTICLE; COLON MOTILITY; COLON TENIA; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE MUSCLE; MALE; MUSCLE RELAXATION; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; COLON; FEMALE; HUMANS; IMIDAZOLES; ISOPROTERENOL; MALE; MIDDLE AGED; MUSCLE RELAXATION; MUSCLE, SMOOTH; PROPANOLAMINES; PROPRANOLOL; RECEPTORS, ADRENERGIC, BETA; TERBUTALINE; TETRAHYDRONAPHTHALENES;

EID: 0033862772     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.3.337     Document Type: Article

References (26)

1. 1 Jacobj C. Beiträge zur physiologischen und pharmakologischen Kenntnis der Darmbewegungen mit besonderer Berücksichtigung der Beziehung der Nebenniere zur Denselben. Arch Exp Pathol Pharmakol 1892;29:171-211.
2. 2 Manara L, Bianchetti A, Croci T, et al. New developments in β-adrenergic-mediated control of intestinal motility: gut-specific phenylethanolamino-tetralines. In: Costa E, ed. Neurochem Pharmacol - A Tribute to B. B. Brodie. New York: Raven Press, 1989:131-44.
3. 3-adrenoceptors and intestinal motility. Fundam Clin Pharmacol 1995;9:332-42.
4. 4 Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol 1948;153:586-600.
5. 5 Lands AM, Arnold A, McAuliff JP, et al. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967;214:597-8.
6. 6 Neely J, Catchpole B. Ileus: the restoration of alimentarytract motility by pharmacological means. Br J Surg 1971;58:21-8.
7. 7 Petri G, Szenohradszky J, Porszasz-Gibiszer K. Sympatholytic treatment of "paralytic" ileus. Surgery 1971;70:359-67.
8. 8 Rees MR, Clark RA, Holdsworth CD, et al. The effect of β-adrenoceptor agonists and antagonists on gastric emptying in man. Br J Clin Pharmacol 1980;10:551-4.
9. 9 Lyrenäs E, Abrahamsson H, Dotevall G. Rectosigmoid motility response to beta-adrenoceptor stimulation in patients with the irritable bowel syndrome. Scand J Gastroenterol 1985;20:1163-8.
10. 10 O'Brien JD, Thompson DG, Holly J, et al. Stress disturbs human gastrointestinal transit via a beta-1 adrenoceptor mediated pathway. Gastroenterology 1985;88:1520.
11. 11 Lyrenäs E, Abrahamsson H. Beta adrenergic influence on oesophageal peristalsis in man. Gut 1986;27:260-6.
12. 3 and atypical β-adrenoceptors. Med Res Rev 1993;13:663-729.
13. 13 Ratkosky DA, Reedy TJ. Choosing near-linear parameters in four parameter logistic model for radioligand and related assay. Biometrics 1986;42:575-82.
14. 14 Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 1959;14:48-57.
15. 15 Tallarida RJ, Murray RB. Manual of pharmacologic calculations with computer programs. New York: Springer-Verlag, 1987:58-61.
16. 16 Bianchetti A, Manara L. In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical β-adrenoceptors in rat colon. Br J Pharmacol 1990; 100:831-9.
17. 3-adrenoceptor agonists of differing selectivities. Pharmacol Exp Ther 1998; 285:1084-95.
18. 3-radrenoceptor antagonist, SR 59230A. Br J Pharmacol 1996;117:1374-6.
19. 19 MacDonald A, McLaughlin DP, Fulton J, et al. Effects of catecholamines on isolated human colonie smooth muscle. J Auton Pharmacol 1996;16:213-20.
20. 20 Kelly J, Sennitt MV, Stock MJ, et al. Functional evidence for a typical β-adrenoceptor in human isolated taenia coli. Br J Pharmacol 1998;10:143-53.
21. 3-adrenoceptors in human colon. Br J Pharmacol 1997;120:1527-35.
22. 3-adrenoceptor-mediated effect. Eur J Pharmacol 1998;353:281-7.
23. 3-radrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes Relat Metab Disord 1996;20: 428-34.
24. 24 Bousquet-Mélou A, Galitzky J, Carpéné C, et al. β-Adrenergic control of lipolysis in primate white fat cells: a comparative study with nonprimate mammals. Am J Physiol 1994;267:115-23.
25. 3-adrenoccptor in the human gastrointestinal tract: an immunohistochemical study. Aliment Pharmacol Ther 1998;12:519-25.
26. 26 Wheeldon NM, McDevitt DG, Lipworth BJ. Do beta 3-adrenoceptors mediate metabolic responses to isoprenaline? Q J Med 1993;86:595-600.